Literature DB >> 18848328

Vaspin serum concentrations in patients with carotid stenosis.

Gabriela Aust1, Olaf Richter, Silvio Rohm, Christiane Kerner, Johann Hauss, Nora Klöting, Karen Ruschke, Peter Kovacs, Byung-Soo Youn, Matthias Blüher.   

Abstract

Obesity is associated with accelerated atherosclerosis. Adipokines may directly influence vessel wall homeostasis by influencing the function of endothelial cells, arterial smooth muscle cells, and modulating inflammation. Recently, visceral adipose tissue-derived serpin (vaspin) was identified as a novel adipokine related to obesity and its metabolic consequences. However, the regulation of vaspin serum concentrations in human atherosclerosis is unknown. We therefore assessed vaspin serum concentrations in 107 consecutive patients with carotid stenosis undergoing carotid endarterectomy (CEA) in relation to severity of atherosclerosis, measures of obesity and circulating markers of obesity and atherosclerosis. Vaspin serum concentrations were significantly lower in patients with carotid stenosis who experienced an ischemic event within 3 months before surgery compared to asymptomatic patients. However, circulating vaspin was not associated with measures of atherosclerosis severity as maximum percentage stenosis. Vaspin serum concentrations were indistinguishable before and after CEA. We found a significant correlation between vaspin and leptin serum concentrations supporting previous results that vaspin closely reflects body fat mass. In conclusion, our data show that low vaspin serum concentrations correlate with recently experienced ischemic events in patients with carotid stenosis despite the lack of an association between circulating vaspin and parameters of atherosclerosis severity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18848328     DOI: 10.1016/j.atherosclerosis.2008.08.028

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  27 in total

Review 1.  [Adipokine update - new molecules, new functions].

Authors:  Carmen Gelsinger; Alexander Tschoner; Susanne Kaser; Christoph F Ebenbichler
Journal:  Wien Med Wochenschr       Date:  2010-08

Review 2.  Vaspin in obesity and diabetes: pathophysiological and clinical significance.

Authors:  Matthias Blüher
Journal:  Endocrine       Date:  2011-12-03       Impact factor: 3.633

3.  Serum vaspin levels are associated with physical activity or physical fitness in Japanese: a pilot study.

Authors:  Nobuyuki Miyatake; Jun Wada; Atsuko Nakatsuka; Noriko Sakano; Sanae Teshigawara; Motohiko Miyachi; Izumi Tabata; Takeyuki Numata
Journal:  Environ Health Prev Med       Date:  2014-01-04       Impact factor: 3.674

4.  Circulating vaspin and visfatin are not affected by acute or chronic energy deficiency or leptin administration in humans.

Authors:  Eun Seok Kang; Faidon Magkos; Elizabeth Sienkiewicz; Christos S Mantzoros
Journal:  Eur J Endocrinol       Date:  2011-03-21       Impact factor: 6.664

Review 5.  Adipokines, adiposity, and atherosclerosis.

Authors:  Longhua Liu; Zunhan Shi; Xiaohui Ji; Wenqian Zhang; Jinwen Luan; Tarik Zahr; Li Qiang
Journal:  Cell Mol Life Sci       Date:  2022-05-03       Impact factor: 9.261

6.  Vaspin alleviates dysfunction of endothelial progenitor cells induced by high glucose via PI3K/Akt/eNOS pathway.

Authors:  Ning Sun; Hui Wang; Lin Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

7.  Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss.

Authors:  Ammon Handisurya; Michaela Riedl; Greisa Vila; Christina Maier; Martin Clodi; Thomas Prikoszovich; Bernhard Ludvik; Gerhard Prager; Anton Luger; Alexandra Kautzky-Willer
Journal:  Obes Surg       Date:  2009-06-09       Impact factor: 4.129

8.  Novel adipokines and bone metabolism.

Authors:  Yuan Liu; Cheng-Yuan Song; Shan-Shan Wu; Qiu-Hua Liang; Ling-Qing Yuan; Er-Yuan Liao
Journal:  Int J Endocrinol       Date:  2013-02-04       Impact factor: 3.257

9.  The serum vaspin levels are reduced in Japanese chronic hemodialysis patients.

Authors:  Junko Inoue; Jun Wada; Sanae Teshigawara; Kazuyuki Hida; Atsuko Nakatsuka; Yuji Takatori; Shoichirou Kojo; Shigeru Akagi; Kazushi Nakao; Nobuyuki Miyatake; John F McDonald; Hirofumi Makino
Journal:  BMC Nephrol       Date:  2012-12-03       Impact factor: 2.388

10.  Vaspin inhibits kallikrein 7 by serpin mechanism.

Authors:  John T Heiker; Nora Klöting; Peter Kovacs; E Bartholomeus Kuettner; Norbert Sträter; Stephan Schultz; Matthias Kern; Michael Stumvoll; Matthias Blüher; Annette G Beck-Sickinger
Journal:  Cell Mol Life Sci       Date:  2013-01-31       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.